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INTRODUCTION 
Multiple sclerosis (MS) is the most frequent chronic disease generating neurologic disability 
in young adults. Among the many symptoms and types of disabilities associated with MS, 
chronic pain seems to be frequent, with an estimated prevalence of pain at any point during 
the course of the patients‟ MS, which ranges from 40% to 92%, depending of the selection 
method of patients and the type of data collection [20,35,36,43]. A recent meta-analysis 
calculated an overall pain prevalence of 63% [15]. 
Pain associated with MS can be classified into three main categories: neuropathic pain (that 
can be constant or intermittent), musculoskeletal pain (i.e., painful tonic spasms, pain 
secondary to spasticity, pain related to being wheelchair-bound), and headaches [35].  The 
prevalence and importance of these three categories of pain vary from one study to another. 
Among specific pain syndromes in MS patients, pain with neuropathic characteristics (NC) 
and headaches are the most prevalent according to the literature [15]. Nonetheless, the co-
occurrence of these two entities has never been studied properly in a single study. The 
prevalence of headache in general and of migraine in particular is higher among MS patients 
compared with the general population, with several authors reporting around 50% of MS 
patients suffering headache [11,15,34,38]. Estimated prevalence of strict migraine in MS 
patients is between 21 and 35%, that is 2.6 times higher than in the general population 
[35,37]. Concerning central neuropathic pain, its prevalence among MS patients has been 
estimated to be around 30%, including neuropathic extremity pain (7.1% to 52.8%), 
Lhermitte‟s sign (9.7% to 25.0%) and trigeminal neuralgia (2.0% to 6.0%) [15]. Thus, the 
prevalence of pain with NC is again higher (five times higher) in MS patients than in the 
general population [6].  Different pain symptoms/syndromes [26,32] can be present in more 
than one body area in individual MS patients [1,36,39,46]. However, how these different pain 
  3 
symptoms/syndromes are related, how they evolve during the course of disease and what is 
the impact of their association in MS patients is not known. 
Limited information is available regarding the epidemiology and characteristics of pain in MS 
patients in France [7]. The purpose of this study was to characterize, by using a postal survey, 
the prevalence and clinical characteristics of pain, with a particular focus on headache and 
pain with neuropathic characteristics (NC), in a large French group of well-defined MS 
patients. The main hypothesis was that migraine headaches and pain with NC were not 
independent. The final goal was to assess the relations between these two types of pain, their 
impact on the quality of life and examined the factors associated with their presence and 
severity in MS patients.  
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METHODS 
Subjects 
The survey was conducted among the members of the “MS patients‟ network in Auvergne”, 
Auvergne being an administrative area in the centre of France. The association was created in 
2003 and the database set-up in 2004. Patients can join this association only if their MS 
diagnosis has been made by a neurologist (no patient‟s relative or self report of the diagnosis). 
When the survey was done (February 2011), patients with Clinically Isolated Syndrome were 
not able to join the association. The patients‟ association database includes demographic 
characteristics, date of diagnosis and date of the first symptoms (MS onset). It is reviewed 
annually to check if patients are still alive and if their postal address and phone numbers are 
still correct. EDMUS (European Database for Multiple Sclerosis) was created in 1990 and has 
been used in Auvergne since 2003. This database is completed by clinicians only and is used 
for the clinical follow-up of patients. It was used to collect data concerning EDSS, disease 
modifying therapy and disease course. The data are reviewed for each patient during each 
follow-up consultation. We have taken for the analysis in this study the most recent available 
data for each patient. The two databases are independent and both are approved by the 
National Commission of Data Processing and Civil Liberties (CNIL), in accordance with 
French law.  The current study was approved by the local ethics committee. 
Survey questionnaire 
A questionnaire was sent to all the 1,300 members of the association in February 2011. A 
cover letter inviting patients to participate in the study accompanied each questionnaire.  
To ensure a maximal response rate, the questionnaire was deliberately simple and it was 
designed to be completed in less than 10 minutes. The first question was “Are you suffering 
or have you suffered during the last month from pain or headache?”. The remainder of the 
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questionnaire only applied to participants who responded positively to this question. Each 
questionnaire was sent with a postage-paid return envelope and it was clearly stated that those 
answering “no” to the first question should return the questionnaire, without completing the 
following pages. There was only one postal survey sent to each patient (no reminders). 
The first part of the questionnaire was about the identification of migraine and repeated the 
second edition of the International Classification of Headache Disorders (ICHD-2), diagnostic 
criteria for strict migraine (category 1.1 for migraine without aura) [47]. This questionnaire is 
similar to the self-administered questionnaire already used in previous French surveys that 
had been validated against face-to-face interviews performed by senior neurologists for the 
diagnosis of strict and probable migraine (formerly “migrainous disorders”) [29]. Probable 
migraine (category 1.6.1 for probable migraine without aura) was identified as migraine 
attacks fulfilling all but 1 of the 4 diagnostic criteria for migraine without aura. In the 2006 
revision of the ICHD-2 (ICHD-2R), new criteria have been proposed in the appendix [21]. 
Chronic migraine (A1.5.1) is characterized by the presence of 15 or more days of headache 
per month for at least 3 months, with headache having the same clinical features of migraine 
without aura for at least 8 of those 15 days, in the absence of medication overuse [41]. In the 
present study, migraineurs (1.1) suffering from headache 15 or more days per month were 
considered to have chronic migraine. 
The subjects answered the two questions (including seven items) from the DN4-interview 
questionnaire regarding the characteristics of their pain [5]. A score of 1 was given to each 
positive item and a score of 0 to each negative item. The total score was calculated as the sum 
of the seven items. Respondents with a total score at 3 or more were considered to have 
neuropathic pain characteristics [5]. Initially, the DN4-interview questionnaire was validated 
as a clinician-administered questionnaire. A complementary validation was made and the 
results of the self-reported and clinician-administered questions for each of the seven items 
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showed excellent consistency (kappa coefficients with 95% CI of 0.82-0.95; p<0.001). The 
self-administered DN4 questionnaire had a sensitivity of 81.6% and a specificity of 85.7% for 
an optimal cut-off score of 3 out of 7, being similar to those observed in the initial study using 
a clinician-administered version of the questionnaire [6]. “S-LANSS” and “7 items DN-4” are 
the most commonly used questionnaires for diagnosis of neuropathic pain. They have similar 
sensitivity and specificity and are both validated for self-administration. We have chosen the 
DN-4 because it is validated in French and because we use it in our daily-practice. Moreover, 
a large study was conducted in France using the same questionnaire, allowing comparison [6]. 
We have used the results of the study by Bouhassira et al., (2008) assessing the prevalence of 
pain with neuropathic characteristics in the general population, as historical controls [6]. We 
have compared, among patients with NC, the use of the 7 pain descriptors using a Chi
2
 test 
(comparison between a theoretical and an observed proportion, bilateral formulation). We 
consider as significant for this test p-values <0.001. 
To assess the severity of pain and the impact on daily functions, the short form of the Brief 
Pain Inventory was used [8]. The results of the four pain intensity scores were pooled together 
in the Pain Severity Index (PSI) and the seven items concerning interference of pain were 
pooled together in the Pain Interference Index (PII). The Sullivan pain catastrophizing scale 
score was also used [44].  
Statistical analysis 
Statistical analysis was performed using Pearson chi-square test (or Fisher exact test if 
needed) testing for relationships between qualitative variables while the Pearson correlation 
coefficient test was used to assess relationships between quantitative variables. Comparing 
binary characteristics regarding quantitative variables, we performed Student t-tests or, if 
needed, Welch‟s tests (taking into account heterogeneity of variances). Regarding some binary 
  7 
variables of particular interest as presence/absence of pain or NC, simple logistic models were 
performed using these variables as response variables and allowing the estimation of odds 
ratio (OR) and their 95% confidence interval (95%CI) towards binary characteristics 
(including dichotomized originally continuous variables). For the 95% CI, the normal 
distribution was assumed as sample sizes were considered large enough (Np and N(1-p)>>5) 
[14]. Further, multiple logistic regressions were performed to adjust simultaneously for 
several explanatory variables (age, sex, age at MS onset, time from MS onset and EDSS). As 
proposed by some statisticians, we have chosen to report all the individual p-values and 
confidence intervals, without doing any mathematical correction for distinct tests comparing 
two modalities [40]. For comparisons concerning three modalities (Tables 5 and Figure 2), we 
have performed first a one way analysis of variance (ANOVA I) and, if ANOVA I was 
significant, we added a multiple comparisons procedure (Tukey honestly significant 
difference test) to detail differences between more than two modalities while keeping the 
family-wise type I error set at 5%. All statistical analyses were performed on SAS® (v9.3, 
SAS institute inc., Cary; NC, USA) with a type I error set at 5%.  
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RESULTS 
Of the 1,300 questionnaires sent, 681 (52.4%; 95%CI: 49.7 – 55.1) were returned and 673 
(i.e. 98.8% of those returned) could be assessed. Demographic characteristics were not 
different between respondents and non-respondents. A total of 529 subjects reported pain 
(Figure 1), which leads to a prevalence of 78.6% (95%CI: 75.5 – 81.7). Sex ratio, time from 
onset and mean EDSS were not significantly different between patients with or without pain. 
Patients with pain were significantly younger than patients without pain. Of these 529 patients 
with pain, 361 reported headache that is 53.6% (95% CI: 49.9 – 57.4) of the respondents. Four 
hundred and eighty-nine subjects reported extra-cephalic pain (i.e. pain other than headache); 
among whom 346 reported pain with neuropathic characteristics (51.4% of the respondents; 
95%CI: 47.6 – 55.2). As patients with primary progressive or secondary progressive MS did 
not behave differently in terms of prevalence of pain, headaches, migraine and pain with NC, 
we present the whole results as relapsing-remitting MS (RR-MS) or not. 
Pain with neuropathic characteristics 
In this survey, we found that pain with neuropathic characteristics (NC) was not explained by 
sex, age or the time from disease onset (table 1). The mean pain intensity, as measured by the 
VAS score was 4.9±0.1, and 36.8% of the respondents had NC pain of moderate to severe 
intensity (≥4/10). Patients with NC reported pain that was more intense. Two out of the seven 
pain descriptors were particularly used by MS patients with NC: “pins and needles” and 
“tingling”. The number of pain locations was higher for patients presenting with NC. Among 
these patients with NC, 58% presented with three or more painful sites and 61% presented 
pain in both upper and lower limbs. The number of painful body sites was positively 
correlated with both the pain severity index (PSI) and pain interference index (PII) (r=0.34, 
p<0.001 and r=0.22, p<0.001 respectively). Moreover, the PSI and PII were positively 
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correlated (r=0.58, p<0.001). The number of pain sites was negatively correlated with age (r=-
0.12, p= 0.008). 
The negative impact of pain on daily living activities was significantly higher for NC pain, 
particularly for mood and sleep (p=0.01). The pain catastrophizing score was higher in 
patients with NC (p<0.001). Finally, migraine was more frequent in patients with NC pain 
(p<0.001). 
Interestingly, only 78 out of the 346 patients presenting pain with NC had a prescription for 
specific anti-neuropathic drugs (59 with antiepileptic drugs, 20 with tricyclic anti-depressants, 
7 with venlafaxine and 5 with duloxetine, some of them receiving both antiepileptic and 
antidepressant drugs) whereas the others had prescriptions of analgesics from the three steps 
ladder of the World Health Organization, benzodiazepines or anti-spastic drugs (Table 2). 
Some patients were not taking any drugs but were using physiotherapy, relaxation or 
hypnosis. Two hundred and forty-eight of the patients presenting pain with NC had a PSI≥4. 
Out of them, 70 were receiving specific drugs, i.e. 28%. 
Headaches 
The 361 patients with headache (table 3) were significantly younger than the other 
respondents (p<0.001) and had a shorter time from onset (p=0.004). Among them, 179 
subjects (26.6%; 95%CI: 23.3 – 29.9) fulfilled all IHS criteria for migraine, thus meeting the 
definition of strict migraine, and 130 (19.3%; 95%CI: 16.3 – 22.3) fulfilled all IHS criteria for 
migraine except 1, thus meeting the definition of probable migraine.  
The sex ratio was not statistically different between migraineurs and non-migraineurs. 
Migraine patients were younger, had shorter disease duration and were more often presenting 
an RR-MS. Patients with migraine had a headache of moderate intensity (6.0±0.1) and 15% of 
patients with strict migraine experienced headaches 15 or more days per month, that is 3.9% 
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of all the respondents. Headaches occurring 15 or more days per month are supposed to be 
chronic migraine provided that there is no medication overuse; medication overuse headache 
(MOH; 8.2 of the IHS classification) in the second case. What is crucial in the definition of 
MOH is that treatment occurs both frequently and regularly, i.e, on 2 or more days each week. 
The questionnaire included the type of medications (e.g., codeine or caffeine-containing ones) 
but unfortunately neither the frequency nor the quantity used by patients. Thus, we cannot 
know whether some patients actually fulfilled the criteria for MOH.  
The number of pain locations was not different between migraineurs and non-migraineurs. 
The EDSS was significantly lower for migraineurs. NC pain was significantly more prevalent 
in patients with migraine. There was a trend for higher prevalence of migraine in patients 
receiving beta-interferon (table 3). Logistic regressions performed among all the respondents 
showed that younger age was associated with both the presence of headache (OR1-2 = 4.98; 
95%CI: 2.44 – 10.10 and OR1-3 = 5.85; 95%CI: 2.87 – 11.90, comparing first and second and 
first and third terciles respectively) and migraine (OR = 3.11; 95%CI: 1.68 – 5.78). RR-MS 
disease course was only associated with migraine (OR = 1.91; 95%CI: 1.12 – 3.26).  
Twenty-four out of the 309 patients (i.e. 7.8%) with strict migraine were taking preventive 
treatment (13 with amitriptyline, 4 with dihydroergotamine, 3 with propranolol, 3 with 
topiramate and 1 with indoramine). For the treatment of the attacks, very few patients had an 
optimal treatment. Only 59 had NSAID and 11 had a triptan (i.e. respectively 19.1% and 
3.6%). All these patients were among the 274 patients with a headache pain above 4/10. 
Among the patients suffering probable migraine 15 or more days per week, some were 
possibly suffering from medication overuse headache. Analgesic drugs consumed are listed in 
table 2. 
Comorbidities 
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Migraine and pain with NC were both found to be present in 32% of the patients (table 4). To 
ensure our sample size was sufficient, we performed a retrospective power calculation. In our 
survey, migraine prevalence is 46% and pain with NC is 51%. If these two entities were 
independent, the co-occurrence would be supposed to be present in only 23.5% of the 
patients. Nonetheless, the observed prevalence for the co-occurrence is 32%. To demonstrate, 
a statistically significant difference between this theoretical and this observed proportion with 
a power of 99% (type I error set at 5%, bilateral formulation), 510 subjects were needed. With 
our 673 respondents, this power is easily reached.  
As described above, patients with migraine were younger, presented more frequently with a 
RR-MS and had a lower EDSS. Pain with neuropathic characteristics was associated with 
numerous pain locations. The proportion of migraine sufferers was higher in the group of 
patients affected by pain with NC, showing the high comorbidity of these two symptoms. In 
the sub-group of patients suffering from both migraine and pain with NC, the headache pain 
intensity and the pain severity index for other types of pain were higher. Moreover, the pain 
interference index and the catastrophizing were also higher in this sub-group. 
Impact of time from MS onset and aging  
As expected, the proportion of RR-MS decreased and EDSS increased with age. Global pain 
prevalence was not significantly different in the different disease duration or age groups, even 
if there was a trend toward lower prevalence among patients with longer MS duration or older 
patients (table 5). Longer disease duration and aging were both associated with lower 
headache and migraine risk. The peak prevalence for pain with NC and for the number of 
painful body sites was between 36 and 54 years old.  
Disease modifying therapies  
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The status for disease modifying treatment was known for 399 patients among the 
respondents (table 6). Patients receiving beta-interferon therapy were younger and had lower 
EDSS. The risk of pain in general and of pain with NC was neither increased nor decreased 
by the disease modifying treatments (Figure 2). The patients undergoing beta-interferon 
treatments presented with a higher rate of headaches and migraine.  
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DISCUSSION 
This study assessed the prevalence and co-occurrence of headaches and neuropathic pain in a 
large French group of well-studied MS patients. MS prevalence in our administrative area 
(Auvergne) is closed to the country-wide one, i.e. 95 per 100,000 inhabitants [17]. Given that 
there are 1,347,387 inhabitants in Auvergne [24], the number of MS patients in this area 
should be 1280, that is, very close to the 1,300 members of the MS patients‟ network. We 
speculate that as MS prevalence is similar to that of the country, the observed pain prevalence 
should also be representative of that in our country. Of the 1300 sent questionnaires, 673 
could be used for statistical analysis. Study patients had a mean age of 50 years, were mostly 
female (80%), had a mean disease duration of almost 15 years and an EDSS of 3.7. A RR-MS 
disease course was present in 74%.  
Pain 
This study confirms that pain is very common in MS patients. Almost 80% of patients 
reported pain in the previous month, with 51% of them suffering NC pain and 46% migraine. 
Moreover NC pain and migraine were both reported by 32% of our MS patients. Such overall 
pain prevalence is in the upper range of those previously reported [15]. Patients with pain 
were younger than those without pain. On the other hand, neither sex ratio, nor mean disease 
duration, nor mean EDSS were significantly different between patients with or without pain. 
Pain with neuropathic characteristics 
In our survey, 51% of patients suffered NC pain. This prevalence is slightly above the 34 to 
49% reported in several previous studies [3,18,46]. It has to be noted, however, that none of 
these studies used questionnaires specifically designed to detect the neuropathic 
characteristics of pain. This likely led to underestimating the actual prevalence of NC pain in 
MS patients. Moreover, most of these studies [3,23,27,31,42,54] used restrictive definitions, 
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some of them reporting only neuropathic extremity pain, leading to a mean prevalence of 27% 
for this symptom alone [15]. Using the very same DN4 questionnaire as here, Truini and 
collaborators [50] found only 14% of their patients suffering neuropathic pain and 5% 
ongoing neuropathic extremity pain. In this latter study, however, the overall pain prevalence 
was strikingly low (30%) and the mean age of patients 39 years. We noted here that the 
prevalence of NC pain significantly decreases in patients younger than 35-years old. It cannot 
be ruled out, however, that self-administration of the DN4 questionnaire, although validated, 
leads to a slight overestimation of NC pain prevalence.  
NC pain was more intense than non-NC pain. NC pain was often located in the limbs and in 
more than one body region. Thus, 58% of NC pain patients reported pain in three or more 
body regions. The number of pain locations, pain intensity and pain interference were 
significantly and positively associated with the report of NC pain. In our study the words 
„pins and needles‟ and „tingling‟ were most frequently used by MS patients to describe their 
NC pain. In previous studies of patients with MS the adjectives most often used to describe 
NC pain were: aching, stabbing, cutting, shooting, pricking, tingling, heavy, dull, cramping, 
smarting and squeezing [36,45,46,51]. It is interesting to note that, compared with the general 
population suffering chronic neuropathic pain, MS patients were more likely to use the pain 
adjectives of „painful cold‟, „tingling‟, „itching‟ and „numbness‟ [6]. Such descriptors of 
neuropathic pain in MS patients could be related to central mechanisms, whereas in the 
general population, neuropathic pain is mostly due to peripheral mechanisms. 
When compared to non-NC pain, NC pain was associated with a higher level of pain 
catastrophizing and stronger interference of pain with daily living activities, particularly for 
mood and sleep. NC pain is known to independently contribute to quality-of-life impairment 
[2]. Our data in this specific population thus confirm that NC pain has a more negative impact 
on quality-of-life than non NC pain. The pain catastrophizing scores in central neuropathic 
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pain are as elevated as in peripheral neuropathic pain [30]. As reported in most studies, no 
link between NC pain and EDSS was found ([25,27,31,36,46];but see [42]). 
Consistent with most previous studies (for review see [35]), gender, age and disease duration 
were not correlated with NC pain. Two studies have reported associations between age or 
disease duration and pain [9,32]. But most cross-sectional studies failed to find any clear 
association between age [3,23] or disease duration [3,23,39,46] and pain. It has also been 
suggested that the prevalence of neuropathic pain increases when the disease has a 
progressive course [31,42,49]. But such a correlation could not be found in many other studies 
[18,19,25,36,46,54]. Disease modifying treatments were associated with the prevalence of 
neither general nor NC pain. Less than a quarter of patients suffering NC pain were receiving 
a specific treatment for neuropathic pain.  
Headaches 
The overall prevalence of headache was 54%, which is within the range of the previously 
reported prevalence [15]. The overall prevalence of migraine was 46%, thus, 2.2 times more 
than in a historical French cohort [29], but consistent with that in a recent meta-analysis [37]. 
As previously reported [53], these patients suffered migraine an average 8 days a month with 
a mean pain intensity of 6. Migraine was episodic in most patients (85%) but headaches were 
occurring 15 or more days per month in a large minority (15%) of them; that is, the overall 
prevalence of chronic migraine in our MS patients was 3.9%, thus, much higher than that in 
the general population (1.4 to 2.2%) [33]. Such a high prevalence has already been reported 
once [53]. Pain catastrophizing was higher in MS patients with migraine than in those with 
other headaches. There was no difference in pain interference between patients with migraine 
and those with other headaches. Migraine was, in addition, associated with younger age, 
shorter disease duration, lower EDSS and RR-MS compared with other headaches. Among 
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disease modifying treatments, patients receiving interferons were more prone to migraine. 
These results are consistent with previous reports [11,13,38,53]. It is noteworthy that only 
11% of migraineurs received a preventive treatment and 21%, a specific treatment for 
migraine attacks. These data confirm the low rate of triptans prescription in MS-migraineurs 
[52]. 
In MS patients suffering from pain, NC was significantly associated with higher risk of 
migraine. When patients had both pain with NC and migraine, they reported higher pain 
severity, more pain interference on usual activities and a higher pain catastrophizing, than 
patients suffering either NC pain or migraine alone. To our knowledge, this is the first study 
showing a correlation between migraine and neuropathic pain, a previous publication having 
provided evidence for correlation between migraine and various other pain-related symptoms, 
such as Lhermitte‟s sign, cranial neuralgia and restless legs syndrome that are 2–5 times 
higher in MS patients with migraine compared with MS patients without headaches [28].  
Possible mechanisms of NC pain and migraine in MS patients 
The prevalence of migraine, higher in young patients, decreases with aging. On the other 
hand, the prevalence of NC pain is maximum between 36- and 54-years old, suggesting that 
NC pain appears early but not at the very beginning of the disease. Interestingly, such age-
dependency of NC pain prevalence in MS patients appears to be different from that in the 
general population which simply increases with age. Thus, in a population-based survey, 
neuropathic pain prevalence is around 5% before the age of 50-years, and around 9% 
thereafter [6]. In addition, our MS patients with migraine had shorter disease duration and 
higher RR-MS than those with NC pain. Our study thus reveals that migraine, but not NC 
pain, is associated with young age, short disease duration, RR-MS and interferons treatment. 
Biondi [4] had hypothesized that migraine is a neuropathic pain syndrome. That risk factors 
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do not similarly affect migraine and NC pain suggests that, on the other hand, these two pain 
syndromes do not rely on the same mechanisms. 
Limitations 
One limitation of this survey is the relatively low response rate (52%), though this response 
rate is close to that of other epidemiological studies using the same methodology 
[12,16,20,22,48]. Nevertheless, the cohort is well-described and non-responders were not 
different from responders concerning demographic and clinical characteristics. The second 
limitation is the lack of information concerning the frequency of analgesics use, making it 
impossible to definitively separate chronic migraine from medication overuse headache. 
Another major limitation is the lack of information about pain duration. In accordance with 
previous studies, we classified patients with or without pain on the basis of self-reported pain 
during the last month [3,7,16,18,20,22,25,46]. Unfortunately, the duration of pain is rarely 
reported in other studies and we did not have this data either. Finally, it is perhaps regrettable 
that the patients did not undergo physical examination to confirm both diagnosis of migraine 
and neuropathic pain. However, the questionnaires used are well-validated, even if a slight 
overestimation is possible.  
Conclusion 
Migraine and NC pain are comorbid in MS and are associated with more intense pain and 
interference on normal activities. Both types of pain are present early in the disease course. 
Migraine seems to be associated with the inflammatory phase of the disease and would 
involve a dysfunctional mechanism, i.e. amplification of nociceptive signaling in the absence 
of either [peripheral tissue] inflammation or neural lesion [10]. Neuropathic pain could rather 
be due to early lesions in the CNS. The correlation between migraine and neuropathic pain 
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deserves further study. Specific therapeutic studies are needed, taking into consideration pain 
specificities associated with MS. 
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TABLE CAPTIONS and LEGENDS 
 
Table 1: Patients with extra-cephalic pain, with or without neuropathic characteristics 
 
Table 2: Treatments used. NSAID: non steroidal anti inflammatory drug; SAID: steroidal anti 
inflammatory drug. 
 
Table 3: Patients with pain, with or without migraine (strict or probable) 
 
Table 4: Patients with pain: co-occurrence of migraine and pain with neuropathic 
characteristics (NC). Patients with both symptoms experienced more intense pain, a higher 
interference on activities of daily living and a higher catastrophizing score. 
 
Table 5: 
A: Prevalence of overall pain and pain subgroups according to time from disease onset. 
B: Prevalence of overall pain and pain subgroups according to age at time of survey. 
For statistical comparisons, first column is referenced as „A‟, second column as „B‟ and third 
column as „C‟. All significant differences (≠) are reported (p<0.05). NS = Non significant.  
 
Table 6: Disease modifying treatments at time of survey 
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FIGURE LEGENDS.  
Figure 1: Main characteristics of the cohort and the different sub-groups 
NC: Neuropathic Characteristics. Continuous variables are displayed as mean ± SEM 
(standard error of the mean). 
 
Figure 2: Impact of disease modifying treatments 
Blue: 120 patients undergoing beta-interferon therapy; Red: 133 patients undergoing other 
disease modifying treatment; Green: 146 patients without any disease modifying treatment  
Continuous variables are displayed as mean ± SEM (standard error of the mean). Binary 
variables are expressed as percent ± IC95%. Statistical results are displayed when significant 
(** for p < 0.01 and *** for p < 0.001). 
